---
title: Silymarin slows Parkinson disease progression
nct_id: NCT07001150
phase: PHASE2
status: RECRUITING
sponsor: Tanta University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07001150"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07001150"
last_fetched: "2026-05-10T14:06:38.416Z"
source: "Parkinson's Pathways (curated)"
---
# Silymarin slows Parkinson disease progression

**Goal (in five words):** Silymarin slows Parkinson disease progression

**Official Title:** Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

**Trial ID:** [NCT07001150](https://clinicaltrials.gov/study/NCT07001150)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Tanta University
- **Target Enrollment:** 50 participants
- **Start Date:** 2025-05-10
- **Completion Date:** 2026-05-30
- **Conditions:** Parkinson Disease
- **Interventions:** levodopa-carbidopa, Silymarin
- **Intervention Types:** DRUG

## Summary For Families

The goal is to see whether silymarin, the active extract from milk thistle, can offer neuroprotection and help manage Parkinson's symptoms by reducing oxidative stress and inflammation that contribute to dopaminergic neuron damage. The approach adds oral silymarin to usual levodopa-carbidopa therapy; silymarin is not a dopamine replacement, it works as an antioxidant and anti-inflammatory agent, and the trial will monitor safety and any interactions with levodopa. This Phase 2 trial plans to enroll about 50 people, ages 45 to 65, who have Parkinson's and are already on dopamine replacement with Hoehn and Yahr stage 1 to 4. People who are pregnant or breastfeeding, have advanced liver disease, morbid obesity, poorly controlled diabetes, recent silymarin use, or other serious illnesses are excluded.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age between 45 and 65 years old
* Both sexes
* Patients with Parkinson's disease on dopamine replacement therapy
* Modified Hoehn and Yahr stage, MHY 1-4 (29)

Exclusion Criteria:

* Subjects \< 18 years of age
* Pregnant or breastfeeding women
* Suspected hypersensitivity to silymarin or multivitamins
* Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
* Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40
* Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7%
* Current use of Silymarin or recent use within the past two weeks.
* Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
```

## Locations (1)

- Tanta Hospital for Mental Health, Tanta, Tanta, Qism 2, Egypt _(30.7885, 31.0019)_
  - Nour A Elsherbeny, Bachelor of Pharmacy — (CONTACT) — 01286911189 — nelsherbeny@horus.edu.eg
  - Nour A Elsherbeny, Bachelor of Pharmacy — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Nour Elsherbeny, MSc — (CONTACT) — 01286911189 — nelsherbeny@horus.edu.eg

---

*Canonical: https://parkinsonspathways.com/trial/NCT07001150*  
*HTML version: https://parkinsonspathways.com/trial/NCT07001150*  
*Source data: https://clinicaltrials.gov/study/NCT07001150*